

1 Electronic Supplementary Information (ESI)

2 **Towards a sustainable generation of pseudopterosin-type
3 bioactives**


4

5 Ringel *et al.*

6


Electronic Supplementary Information (ESI)

Towards a sustainable generation of pseudopterosin-type bioactives - Ringel et al. 2020



7


8 Figure S 1: Growth curve of *E. coli* host harbouring terpene biosynthesis precursor plasmid
9 and plasmid coding for HpS; error bars show standard deviation calculated from triplicates
10 (measurements of OD₆₀₀).



11


12 Figure S 2: Time dependent, total terpene yield from fermentation (HpS) shown in Figure S1;
13 error bars show standard deviation calculated from duplicates (quantification from GC-FID
14 measurements).

15



16

17 Figure S 3: Growth curve of *E. coli* host harbouring terpene biosynthesis precursor plasmid
 18 and plasmid coding for HpS M75L; error bars show standard deviation calculated from
 19 triplicates (measurements of OD₆₀₀).



20


21 Figure S 4: Time dependent, total terpene yield from fermentation (HpS M75L) shown in
 22 Figure S3; error bars show standard deviation calculated from duplicates (quantification from
 23 GC-FID measurements).

24

Electronic Supplementary Information (ESI)

Towards a sustainable generation of pseudopterosin-type bioactives - Ringel et al. 2020

25



26


27 Figure S 5: GC-MS spectra of HpS' main products (obtained in *E. coli*); (A) isoelisabethatriene
28 A; (B) isoelisabethatriene B; (C) hydropyrene; (D) hydropyrenol

29

30

Electronic Supplementary Information (ESI)

Towards a sustainable generation of pseudopterosin-type bioactives - Ringel et al. 2020



31

32 **Figure S 6:** Comparison of GC-MS spectra of isoelisabethatriene A (A and C) and B (B and D)
33 from wild-type HpS and HpS M75L; (A) and (B): wt HpS; (C) and (D): HpS M75L. The isoforms
34 produced in different enzyme variants show identical fragmentation patterns.


35

36

37 Table S 1: NMR data of isoelisabethatriene A (HpS wild-type); Standardised on solvent
 38 (benzene-d₆) peak: ¹H = 7.16 ppm, ¹³C = 128.06 ppm

C	Art	¹ H [ppm]	Multiplet	Integral	¹³ C [ppm]
1	CH	2.18	m	1	34.07
2	CH ₂	1.81	m	1	31.87
		1.21	m	1	
3	CH ₂	1.65	m	1	21.17
		1.42	m	1	
4	CH	2.24	m	1	41.28
5	CH	5.78	s	1	122.77
6	C _q	-			132.33
7	CH ₂	2.08	m	1	29.22
		1.84	m	1	
8	CH ₂	2.18	m	1	27.50
		1.94	m	1	
9	C _q	-			133.38
10	C _q	-			130.31
11	CH	2.00	m	1	34.49
12	CH ₂	1.44	m	1	35.88
		1.37	m	1	
13	CH ₂	2.10	m	1	26.92
		2.07	m	1	
14	CH	5.27	m	1	125.57
15	C _q	-			130.94
16	CH ₃	1.59	s	3	17.82
17	CH ₃	1.71	s	3	25.90
18	CH ₃	0.84	d	3	15.07
19	CH ₃	1.76	s	3	23.36
20	CH ₃	0.97	d	3	19.36


39



40


41

42



44 Figure S 7: ¹H NMR spectrum of isoelisabethatriene A produced by wild-type HpS.

45



46 47 Figure S 8: ¹³C NMR spectrum of isoelisabethatriene A produced by wild-type HpS.

48


Electronic Supplementary Information (ESI)

Towards a sustainable generation of pseudopterosin-type bioactives - Ringel et al. 2020

49 Table S 2: Comparison of ^{13}C -NMR spectra of isoelisabethatriene A produced in HpS, HpS
50 M75L and HpS M75F, respectively.

C	Literature ¹		Measurements conducted in C_6D_6		
	Art	WT δ ^{13}C (175 MHz)	WT δ ^{13}C (126MHz, Cryo)	M75L δ ^{13}C (75 MHz)	M75F δ ^{13}C (75 MHz)
1	CH	34.07	34.0	34.0	34.0
2	CH_2	31.87	31.5	31.5	31.5
3	CH_2	21.17	21.0	21.0	21.0
4	CH	41.28	41.0	41.0	41.0
5	CH	122.77	122.7	122.7	122.7
6	C_q	132.33	132.3	132.3	132.3
7	CH_2	29.22	29.0	29.0	29.0
8	CH_2	27.50	27.4	27.4	27.4
9	C_q	133.38	133.2	133.2	133.2
10	C_q	130.31	130.3	130.3	130.3
11	CH	34.49	34.4	34.4	34.4
12	CH_2	35.88	35.7	35.7	35.7
13	CH_2	26.92	26.8	26.8	26.8
14	CH	125.57	125.6	125.6	125.6
15	C_q	130.94	130.9	130.9	130.9
16	CH_3	17.82	17.8	17.8	17.8
17	CH_3	25.90	25.9	25.9	25.9
18	CH_3	15.07	15.0	15.0	15.0
19	CH_3	23.36	23.2	23.2	23.2
20	CH_3	19.36	19.2	19.2	19.2

51



52

53

54


Electronic Supplementary Information (ESI)

Towards a sustainable generation of pseudopterosin-type bioactives - Ringel et al. 2020

55 Table S 3: NMR data of isoelisabethatriene B (wild-type) Standardised on solvent (benzene-
56 d₆) peak: ¹H = 7.16 ppm, ¹³C = 128.06 ppm.

C	Art	¹ H [ppm]	Multiplet	Integral	¹³ C [ppm]
1	C _q	-			130.20
2	CH ₂	1.91 2.00	m m	1 1	32.73
3	CH ₂	1.53 1.20	m m	1 1	21.63
4	CH	1.34	m	1	43.33
5	CH	5.61	m	1	124.68
6	C _q	-			133.77
7	CH ₂	1.91 1.88	m m	1 1	32.09
8	CH ₂	2.70	m	2	27.00
9	C _q	-			123.95
10	CH	2.67	m	1	39.61
11	CH	1.96	m	1	31.60
12	CH ₂	1.37	m	2	36.01
13	CH ₂	2.04	m	2	26.36
14	CH	5.22	m	1	125.29
15	C _q	-			130.69
16	CH ₃	1.56	s	3	17.58
17	CH ₃	1.69	s	3	25.53
18	CH ₃	0.82	d	3	13.96
19	CH ₃	1.66	s	3	23.57
20	CH ₃	1.65	s	3	18.40


57



58

59


60



61

62 Figure S 9: ¹H NMR spectrum of isoelisabethatriene B produced by wild-type HpS.

63



64 65 Figure S 10: ¹³C NMR spectrum of isoelisabethatriene B produced by wild-type HpS.

66


Electronic Supplementary Information (ESI)

Towards a sustainable generation of pseudopterosin-type bioactives - Ringel et al. 2020

67 Table S 4: Comparison of ^{13}C -NMR spectra of isoelisabethatriene B produced in HpS, HpS
68 M75L and HpS M75F, respectively

Literature (CDCl_3) ²			Measurements conducted in C_6D_6		
Nr. C	Art	δ ^{13}C	WT δ ^{13}C (75 MHz)	M75F δ ^{13}C (101 MHz)	M75L δ ^{13}C (75 MHz)
1	C_q	130.0	130.20	130.5	130.5
2	CH_2	32.4	32.73	32.9	32.9
3	CH_2	21.5	21.63	22.0	22.0
4	CH	43.2	43.33	43.6	43.6
5	CH	124.4	124.68	124.2	124.2
6	C_q	134.2	133.77	134.1	134.1
7	CH_2	31.9	32.09	32.4	32.4
8	CH_2	26.7	27.00	27.3	27.3
9	C_q	124.5	123.95	125.0	125.0
10	CH	39.2	39.61	39.7	39.7
11	CH	31.5	31.60	31.9	31.9
12	CH_2	35.8	36.01	36.3	36.3
13	CH_2	26.2	26.36	26.7	26.7
14	CH	124.9	125.29	125.6	125.6
15	C_q	131.2	130.69	131.0	131.0
16	CH_3	18.0	17.58	17.8	17.8
17	CH_3	25.7	25.53	25.9	25.9
18	CH_3	13.9	13.96	14.3	14.3
19	CH_3	23.5	23.57	23.9	23.9
20	CH_3	18.5	18.40	18.8	18.8

69



70

71

Electronic Supplementary Information (ESI)

Towards a sustainable generation of pseudopterosin-type bioactives - Ringel et al. 2020

13	IGRSSVPY LEECTRRFQEMFDHVVTPTKVL TDAELREVIDOCNAAVAPLGKTVSDERWISYVGVLWSQSPPRHKDMEFKAVCVLNCVTFVNDMPALHD	118
CotB2 0000	PLSRPVHPE GERADAYA VEMLR-GVGLMADEADAAPVLAVGLRLAACYV-----	
Hps 0001	-----DENASWDTLAFMTILMAYAAYEDRAIDSTG	92
	11	
14	FGLFLPQLRKICEKYGYG FEADAEVAYEARAFVTSODHMFRDSPKAALCTTSPEQYFRFRTDIGVDFWNKMSY	192
CotB2 0000	-----	
Hps 0001	AIGLDTDAEVAELHRLAEGTLDRDPAPPDSFVORGladWvRTLNGLASDWDRAAFDVTTLRYFEAM--RYERYVNIRGIPPTPSAH1GMRSHGhvGMYILGAA	196

```

CotB2 0000 --IYR-PEFTEHAKTSLAARMTRGLTIVDFSYDREVSLGQITNCFRLCDVSDTAFKEFFQ-----ARLDOMIEDECIKAIFDQ-----LTQDVFLDLIYGFVVTTSNKRYKTAVID 301
Hp5 0001 UNGYRPERRVLDHAARVRELETLAANYTSWANDLHSFAREHRNQVNNLVSHH-HEGLTFPQQAADRVADLCDEKELAAYLELRQLTPELGIPLTGATGRHVRFLEDNMISMVNDUASARSARYDVVPEA 320

```

72

73 Figure S 11: Alignment of secondary structure elements of CotB2 and HpS. Red: α -helices;
74 blue: β -sheet. The secondary structure of both diterpene synthases match in the positions of
75 their respective α -helices (HHPred³ and Ali2D using PSIPRED⁴ and MEMSAT⁵).

76

77 Figure S 12: Structure alignment CotB2 and HpS. Identical amino acids (AA) are highlighted
78 in deep purple, similar AA are marked in light purple, AA with no corresponding match coloured
79 in pink; highly conserved motifs are framed by a red box.

80

Electronic Supplementary Information (ESI)

Towards a sustainable generation of pseudopterosin-type bioactives - Ringel et al. 2020




Figure S 13: Evaluation of the HpS' product spectrum (black: wild-type; pink: M75L and blue: M75F) with corresponding MS spectra. Whole spectrum of crude *E. coli* extract. (1) isoelisabethatriene B; (2) isoelisabethatriene A; (3) hydropyrene.




Figure S 14: Zoom into figure S 14 to enhance comparison of main products: (1) isoelisabethatriene B; (2) isoelisabethatriene A; (3) hydropyrene. Black: wild-type HpS; blue: HpS M75F; pink: HpS M75L.




Figure S 15: GC chromatogram after 1 month storage of extract in hexane gained from HpS M75F. Analysis of compound with retention time 20.94 min (Figure S 16) showed spontaneous formation of erogorgiaene.

Electronic Supplementary Information (ESI)

Towards a sustainable generation of pseudopterosin-type bioactives - Ringel et al. 2020




Figure S 16: GC-MS spectra analysis of compounds highlighted in figure S 16. (A) 20.46 min: isoelisabethatriene A, (B) 20.87 min: isoelisabethatriene B, (C) 20.94 min: erogorgiaene, (D) 21.73 min: hydropyrene




Figure S 17: GC chromatogram of mono hydroxylated diterpene (retention time 22.28 min) identified in HpS M75L extract.




Figure S 18: GC-MS spectrum of hydroxylated diterpene (retention time 22.28 min) identified in HpS M75L extract with respective parent ion mass of 290.




Figure S 19: Time resolved monitoring of CalB mediated conversion of isoelisabethatriene B. Blue: isoelisabethatriene B; green: isoelisabethatriene B monoepoxide; yellow: isoelisabethatriene B diepoxides.

Electronic Supplementary Information (ESI)

Towards a sustainable generation of pseudopterosin-type bioactives - Ringel et al. 2020




Figure S 20: GC-MS-chromatogram – isoelisabethatriene B monoepoxide; Total Ion Count (TIC) Recording started at 18 min.




Figure S 21: Comparison of GC-MS spectra of isoelisabethatriene B (A) and the monoepoxide product 1R-epoxy-5,14- elisabethadiene (B), respectively.





Figure S 22: GC MS spectrum of putative isoelisabethatriene B derived diepoxide with parent ion mass m/z 304; Retention time R_t = 22.42 min.

Electronic Supplementary Information (ESI)

Towards a sustainable generation of pseudopterosin-type bioactives - Ringel et al. 2020

Table S 5: NMR data of 1*R*-epoxy-5,14- elisabethadiene; Standardised on solvent (benzene-d₆) peak: ¹H = 7.16 ppm, ¹³C = 128.06 ppm.

Position	C [ppm]	H [ppm]	Multiplet	Integral	J-Coupling Constant [Hz]	COSY	HMBC	HSQC	NOESY
1	62.66	-					20		
2a	32.68	1.42	m	1		2b	20	yes	2b; 20
2b	32.68	1.87	m	1		3a; 2a	20	yes	2a
3a	18.02	1.60	m	1		3b; 4		yes	3b
3b	18.02	1.09	m	1		2b; 3a		yes	3a
4	44.83	1.03	m	1			10	18	yes
5	125.89	5.42	s	1			10; 19	19	yes
6	132.90	-					19		
7a	29.87	1.74	m	1		8a	5	yes	
7b	29.87	1.94	m	1		8b		yes	
8a	29.68	1.97	m	1		7a		yes	5; 20
8b	29.68	1.66	m	1		7b		yes	10
9	64.21	-						5; 8; 20	
10	38.83	2.47	d	1	10.04	4; 5		yes	5; 18
11	33.33	1.67	m	1		12; 18	12. 18	yes	5; 18
12	35.85	1.29	m	2		11; 13	13; 18	yes	4; 14; 18
13	26.63	2.02	m	1		12; 14	14	yes	11; 14
14	125.44	5.20	t	1	7.14	13; 16; 17	13; 16; 17	yes	12; 13; 16
15	131.04	-					16; 17		
16	25.98	1.69	s	3		14	15; 17	yes	14; 18
17	17.82	1.56	s	3		14	15; 16	yes	
18	14.67	0.81	d	3	6.83			yes	3b; 8b; 10; 11; 12
19	23.61	1.62	s	3		5	5; 6	yes	5
20	19.0	1.22	s	3			1; 2; 9	yes	2b;8b






Figure S 23: ¹H NMR Spectrum of 1*R*-epoxy-5,14- elisabethadiene.

Electronic Supplementary Information (ESI)

Towards a sustainable generation of pseudopterosin-type bioactives - Ringel et al. 2020




Figure S 24: ¹³C NMR Spectrum of 1*R*-epoxy-5,14- elisabethadiene.




Figure S 25: ¹³C DEPT spectra of 1*R*-epoxy-5,14- elisabethadiene.




Figure S 26: ^1H - ^1H COSY spectrum of 1*R*-epoxy-5,14- elisabethadiene.




Figure S 27: ^1H - ^{13}C HSQC spectrum of 1*R*-epoxy-5,14- elisabethadiene.




Figure S 28: ¹H-¹³C HMBC spectrum 1*R*-epoxy-5,14- elisabethadiene.




Figure S 29: ¹H-¹H NOESY spectrum of 1*R*-epoxy-5,14- elisabethadiene.




Figure S 30: Time resolved ergorgiaene formation upon treatment of isoelisabethatriene A with CalB (0 min to 90 min).

Electronic Supplementary Information (ESI)

Towards a sustainable generation of pseudopterosin-type bioactives - Ringel et al. 2020




Figure S 31: GC-MS – chromatogram of erogorgiaene; Total ion Count recording started at 6 min.





Figure S 32: Comparison of GC-MS spectra of erogorgiaene. (A) Derived from Lipase-mediated isoelisabethatriene A conversion. (B) Originating from a coral extract.

Electronic Supplementary Information (ESI)

Towards a sustainable generation of pseudopterosin-type bioactives - Ringel et al. 2020

Table S 6: NMR data of erogorgiaene; Standardised on solvent (CDCl_3) peak: ^1H = 7.26 ppm, ^{13}C = 77.2 ppm.

Position	C [ppm]	H [ppm]	Multiplet	Integral	J-Coupling Constant [Hz]	COSY	HMBC	HSQC	NOESY
1	32.95	2.72	m	1	10.9	2b; 20	20	yes	2b; 3b; 8; 20
2a	31.95	1.34	m	1		2b	20	yes	2b
2b	31.95	1.94	m	1		1; 2a		yes	2a
3a	21.68	1.82	m	1		3b; 4		yes	3b
3b	21.68	1.55	m	1		3a		yes	3a
4	41.64	2.87	m	1	10.2	3a; 18	18	yes	2a; 3a; 5; 11; 12a
5	128.24	7.02	s	1		19	7; 19	yes	11
6	134.85	-					8; 19		
7	126.11	6.94	d	1	8.01	8; 19	5; 19	yes	
8	126.55	7.13	d	1	8.01	7		yes	20
9	140.55	-					8; 20		
10	140.07	-					5; 8		
11	37.11	2.14	m	1		4; 12a; 18	18	yes	4; 5; 18
12a	35.38	1.44	m	1		11	18	yes	
12b	35.38	1.35	m	1		13		yes	
13a	26.46	2.08	m	1		12b; 14		yes	
13b	26.46	2.00		1				yes	
14	125.02	5.17	m	1	7.0	13; 16; 17	16; 17	yes	12ab; 13ab; 17
15	131.45	-					16; 17		
16	25.98	1.72	s	3		14	15; 17	yes	
17	17.88	1.64	s	3		14	15; 16	yes	
18	14.67	0.64	d	3	6.83			yes	11; 2b; 3b
19	21.34	2.30	s	3		5; 7	5; 7	yes	
20	22.01	1.26	d	3	6.92	1		yes	1; 8






Figure S 33: ¹H NMR spectrum of erogorgiaene.




Figure S 34: ¹³C NMR spectrum of erogorgiaene.

Electronic Supplementary Information (ESI)

Towards a sustainable generation of pseudopterosin-type bioactives - Ringel et al. 2020




Figure S 35: ^{13}C DEPT spectra of erogorgiaene.




Figure S 36: ^1H - ^1H COSY spectrum of erogorgiaene.




Figure S 37: ¹H-¹³C HSQC spectrum of erogorgiaene.




Figure S 38: ¹H-¹³C HMBC spectrum of erogorgiaene.




Figure S 39: ^1H - ^1H NOESY spectrum of erogorgiaene.




Figure S 40: Postulated mechanism for formation of (-)-erogorgiaene via epoxidation, dehydration and subsequent spontaneous aromatization.

Electronic Supplementary Information (ESI)

Towards a sustainable generation of pseudopterosin-type bioactives - Ringel et al. 2020

Table S 7: Summary of approximate costs for biotechnological production of erogorgiaene

SUMMARY	#	Items	Description	Cost
	1	CAPEX	Total /10 years depreciation	1,449,732.11
	2	OPEX	Including: Maintenance, insurance and utility	1,464,014.73
	3	RM		23,055,842.10
			Total cost	25,969,589
		Revenues	Kg of Product /yr.	2,829
			Unit cost	9,181.17

Table S 8: Capital Investment for biotechnological production of erogorgiaene

Capital Investment									
#	Item	Unit Purchased	Quantity			Cost	Installation factor	Installed Cost	Ref.
			In process	Standby	Total				
1	Fermenter, Vessel Volume = 200.00 m ³	2,266,000	2	0	2	4,532,000	1.6	7,251,200	SuperPro Designer (V10) Built-in cost model (Year analysis 2020)
2	Stirred Reactor Vessel Volume = 10 m3	53,000	1	0	1	53,000	1.3	68,900	SuperPro Designer (V10) Built-in cost model (Year analysis 2020)
3	Blending Tank, Vessel Volume = 150.00 m3	192,000	1	0	1	192,000	1.3	249,600	SuperPro Designer (V10) Built-in cost model (Year analysis 2020)
4	Decanter Centrifuge, Throughput = 200 m3/h	262,000	1	0	1	262,000	1.6	419,200	SuperPro Designer (V10) Built-in cost model (Year analysis 2020)
5	Distillation column,Volume = 100.00 m3	546,000	1	0	1	546,000	1.6	873,600	SuperPro Designer (V10) Built-in cost model (Year analysis 2020)
6	Inoculum preparation, Vessel Volume = 5.00 m3	-	1	0	1	-	1.3	-	SuperPro Designer (V10) Built-in cost model (Year analysis 2020)
7	Chromatography unit, 0.5D*2.5H	268,000	1	0	1	268,000	1.3	348,400	SuperPro Designer (V10) Built-in cost model (Year analysis 2020)
8	Centrifugal Extraction, Vol. 1000	462,000	1	0	1	462,000	1.6	739,200	SuperPro Designer (V10) Built-in cost model (Year analysis 2020)
9	Unlisted (10* of total PC)					631,500.0	1	631,500	SuperPro Designer (V10) Built-in cost model (Year analysis 2020)
	Total+ intrest 6%							11,216,496	

Table S 9: Total direct costs (TDC) for biotechnological production of erogorgiaene

#	Item	Unit cost	Quantity			Factor	Cost	Ref.
			In process	Standby	Total			
1	Warehouse ,On-site storage of equipment and supplies.	448,660	1	-	1	0.04	448,659.84	Estimated as: 4.0% of the ISBL
2	Site development, Includes fencing, curbing, parking lot, roads, well drainage, rail system, soil borings, and general paving. This factor allows for minimum site development assuming a clear site with no unusual problems such as right-of-way, difficult land clearing, or unusual environmental problems.	1,009,485	1	-	1	0.090	1,009,484.64	Estimated as: 9% of the ISBL
3	Additional piping, Includes fencing, curbing, parking lot, roads, well drainage, rail system, soil borings, and general paving. This factor allows for minimum site development assuming a clear site with no unusual problems such as right-of-way, difficult land clearing, or unusual environmental problems.	504,742	1	-	1	0.045	504,742.32	Estimated as: 4.5% of the ISBL
	Total						1,962,886.80	
	Total Direct Costs (TDC)						13,179,382.80	

Electronic Supplementary Information (ESI)

Towards a sustainable generation of pseudopterosin-type bioactives - Ringel et al. 2020

Table S 10: Total capital investment (TCI) for biotechnological production of ergorgiaene

1	Indirect costs; Start-up and commissioning costs. Land, rights-of-way, permits, surveys, and fees. Piling, soil compaction/dewatering, unusual foundations. Sales, use, and other taxes. Freight, insurance in transit, and import duties on equipment, piping, steel, instrumentation, etc. Overtime pay during construction. Field insurance. Project team. Transportation equipment, bulk shipping containers, plant vehicles, etc.						0.100	1,317,938	Estimated as: 10% of total direct cost (TDC)
	Total							1,317,938.28	
Total Capital Investment (TCI)							14,497,321		
Depreciation 10 year							1,449,732		

Table S 11: Annual operation cost for biotechnological production of ergorgiaene

Annual Operation Cost									
#	Item	Unit cost	Unit	Quantity		Factor	Cost	Ref.	
1	Maintenance					0.03	395,381.48	Estimated as 3% of total direct fixed capital	
2	Property insurance					0.007	101,481.25	Estimated as 0.7% of total Capital Investment (TCI)	
3	Std Power	0.1		4,760,231			476,023.11	the consumption amount based on SuperPro Designer (V10). The cost of kW-h is based on German price of Std power	
4	Steam	1.0	\$/MT	34,233			34,232.91		
5	Chilled water	0.50	\$/MT	911,016			455,508.20		
6	Consumable			1,388			1,387.77		
	Total						1,464,015		
	Total fixed operating costs								

Table S 12: Raw material cost for biotechnological production of ergorgiaene

RM Cost									
#	Item	Unit cost	Unit	Quantity		Factor	Cost	Ref.	
1	Glycerol	0.3	Kg	313,971		1.00	78,492.86	biofuel waste stream	
2	K2HPO4	1.5	Kg	31,114		1.00	46,671.43	Sigma with 30% save due to bulk procurement	
3	KH2PO4	1.5	Kg	5,657		1.00	8,485.71	Sigma with 30% save due to bulk procurement	
4	(NH4)2H2PO4	1.5	Kg	11,314		1.00	16,971.43	Sigma with 30% save due to bulk procurement	
5	Citric acid	1.0	Kg	4,809		1.00	4,808.57	Sigma with 30% save due to bulk procurement	
6	Yeast extract	3.0	Kg	14,143		1.00	42,428.57	Sigma with 30% save due to bulk procurement	
7	propionic acid	1.0	L	16,398		1.00	16,397.52	Sigma with 30% save due to bulk procurement	
8	urea-hydrogen peroxide	1.0	Kg	163,975		1.00	163,975.16	Sigma with 30% save due to bulk procurement	
9	CalB (immobilized on beads)	30.0	Kg	163,975		1.00	4,919,254.66	Sigma with 30% save due to bulk procurement	
10	Ethanol	13.0	L	67,347		95%	878,345.86	95% recovery and 5% loss	
11	Hexane	33.7	L	101,020		90%	3,403,125.00	90% recovery and 10% loss	
12	EtOAc	11.6	L	77,449		90%	899,957.14	90% recovery and 10% loss	
13	Methanol	20.2	L	11,449		90%	231,078.57	90% recovery and 10% loss	
14	Acetonitril	60.7	L	13,469		95%	817,928.57	95% recovery and 5% loss	
	Total						11,527,921.05		
	Total RM Costs (TRM)							23,055,842.10	

Electronic Supplementary Information (ESI)

Towards a sustainable generation of pseudopterosin-type bioactives - Ringel et al. 2020

Table S 13: Summary of approximate costs for chemical synthesis of erogorgiaene

SUMMARY	#	Items	Description	Cost
	1	CAPEX	Total /10 years depreciation	232,470.08
	2	OPEX	Including: Maintenance, insurance and utility	102,195.25
	3	RM		5,736,249.18
			Total cost	6,070,915
		Revenues	Kg of Product /yr.	286
			Unit cost	21,194.54

Table S 14: Capital investment for chemical synthesis of erogorgiaene

Capital Investment									
#	Item	Unit Purchased	Quantity			Cost	Installation factor	Installed Cost	Ref.
			In process	Standby	Total				
1	Stirred Reactor Vessel Volume = 10 L	10,000	1	0	1	10,000	1.3	13,000	SuperPro Designer (V10) Built-in cost model (Year analysis 2020)
2	Stirred Reactor Vessel Volume = 20 L	12,000	1	0	1	12,000	1.3	15,600	SuperPro Designer (V10) Built-in cost model (Year analysis 2020)
3	Stirred Reactor Vessel Volume = 150 L	20,000	1	0	1	20,000	1.3	26,000	SuperPro Designer (V10) Built-in cost model (Year analysis 2020)
4	Stirred Reactor Vessel Volume = 500 L	300,000	1	0	1	300,000	1.3	390,000	SuperPro Designer (V10) Built-in cost model (Year analysis 2020)
5	Centrifugal Extraction, Vol. 100	20,000	1	0	1	20,000	1.3	26,000	SuperPro Designer (V10) Built-in cost model (Year analysis 2020)
6	Centrifugal Extraction, Vol. 1000	36,000	1	0	1	36,000	1.3	46,800	SuperPro Designer (V10) Built-in cost model (Year analysis 2020)
7	Chromatography unit, 0.5D*2.5H	268,000	1	0	1	268,000	1.3	348,400	SuperPro Designer (V10) Built-in cost model (Year analysis 2020)
8	Distillation column,Volume = 100.00 m3	546,000	1	0	1	546,000	1.3	709,800	SuperPro Designer (V10) Built-in cost model (Year analysis 2020)
9	Unlisted (10* of total PC)					121,200.0	1	121,200	SuperPro Designer (V10) Built-in cost model (Year analysis 2020)
						Total+ Interest 6%		1,798,608	

Table S 15: Total direct costs (TDC) for chemical synthesis of erogorgiaene

#	Item	Unit cost	Quantity			Factor	Cost	Ref.
			In process	Standby	Total			
1	Warehouse ,On-site storage of equipment and supplies.	71,944	1	-	1	0.04	71,944.32	Estimated as: 4.0% of the ISBL
2	Site development, Includes fencing, curbing, parking lot, roads, well drainage, rail system, soil borings, and general paving. This factor allows for minimum site development assuming a clear site with no unusual problems such as right-of-way, difficult land clearing, or unusual environmental problems.	161,875	1	-	1	0.090	161,874.72	Estimated as: 9% of the ISBL
3	Additional piping, Includes fencing, curbing, parking lot, roads, well drainage, rail system, soil borings, and general paving. This factor allows for minimum site development assuming a clear site with no unusual problems such as right-of-way, difficult land clearing, or unusual environmental problems.	80,937	1	-	1	0.045	80,937.36	Estimated as: 4.5% of the ISBL
						Total	314,756.40	
						Total Direct Costs (TDC)	2,113,364.40	

Electronic Supplementary Information (ESI)

Towards a sustainable generation of pseudopterosin-type bioactives - Ringel et al. 2020

Table S 16: Total capital investment (TCI) for chemical synthesis of erogorgiaene

1	Indirect costs; Start-up and commissioning costs. Land, rights-of-way, permits, surveys, and fees. Piling, soil compaction/dewatering, unusual foundations. Sales, use, and other taxes. Freight, insurance in transit, and import duties on equipment, piping, steel, instrumentation, etc. Overtime pay during construction. Field insurance. Project team. Transportation equipment, bulk shipping containers, plant vehicles, etc.						0.100	211,336	Estimated as: 10% of total direct cost (TDC)
Total									211,336.44
Total Capital Investment (TCI)									2,324,701
Depreciation 10 year									232,470

Table S 17: Annual operation cost for chemical synthesis of erogorgiaene

Annual Operation Cost									
#	Item	Unit cost	Unit	Quantity		Factor	Cost	Ref.	
1	Maintenance					0.03	63,400.93	Estimated as 3% of total direct fixed capital	
2	Property insurance					0.007	16,272.91	Estimated as 0.7% of total Capital Investment (TCI)	
3	Utility					0.01	21,133.64	the consumption amount based on SuperPro Designer (V10). The cost of kW-h is based on German price of Std power	
6	Consumable			1,388			1,387.77		
Total							102,195		
Total fixed operating costs									

Electronic Supplementary Information (ESI)

Towards a sustainable generation of pseudopterosin-type bioactives - Ringel et al. 2020

Table S 18: Raw material cost for chemical synthesis of erogorgiaene

RM Cost									
#	Item	Unit cost	Unit	Quantity/yr.		Recovery factor	Bulk Factor	Cost	Ref.
1	triethylamine	114.13	L	2,940.35		1.00	0.70	234,907.66	
2	formic acid	50.85	L	1,345.00		1.00	0.70	47,875.18	
3	4-methylacetophenone	171.76	kg	454.48		1.00	0.70	54,642.59	
4	NaHCO3	5.65	kg	33,397.95		1.00	0.70	132,088.88	
5	MgSO4	5.65	kg	65,117.41		1.00	0.70	257,539.34	
6	THF	27.06	L	6,566.58		1.00	0.70	124,400.20	
7	sodium tert-butoxide	366.12	kg	35.22		1.00	0.70	9,026.51	
8	tert-butyl acrylate	186.45	L	596.96		1.00	0.70	77,912.44	
9	TMEDA	124.30	L	836.32		1.00	0.70	72,768.37	
10	MgBr2	1,785.40	kg	653.00		1.00	0.70	816,109.51	
11	KHSO4	101.70	kg	10,747.90		1.00	0.70	765,142.89	
12	toluene	22.04	L	22,430.40		0.10	0.70	34,597.77	
13	TBAF-3H2O	1,979.76	kg	1,300.96		1.00	0.70	1,802,916.16	
14	polyphosphoric acid	79.55	L	5,709.56		1.00	0.70	317,944.59	
15	HCl	339.00	L	1,058.10		1	0.70	251,087.78	
16	(R)-RuCl{[(1S,2S)-pTsNCH(C6H5)CH(C6H5)NH2](η6-p-cymene)}	187,580.00	kg	111.87		0.001	1.00	20,984.78	
17	EtOAc	18.76	L	455,331.59		0.100	0.70	597,877.70	
18	N,N-Diisopropylcarbamoyl chloride	7,774.40	kg	1,115.80		0.001	1.00	8,674.71	
19	CH2Cl2	115.26	L	178,968.01		0.100	0.70	1,443,949.69	
20	CuCl	11,920.00	kg	32.83		0.001	1.00	391.37	
21	DPEPhos	8,452.40	kg	65.67		0.001	1.00	555.03	
22	Bis(pinacolato)diboron	1,511.94	kg	1,092.44		0.001	1.00	1,651.70	
23	MeOH	32.58	L	3,845.29		0.100	0.70	8,770.01	
24	EtZO	60.77	L	33,726.59		0.100	0.70	143,466.90	
25	s-BuLi	299.45	L	4,005.29		0.001	1.00	1,199.38	
26	RuCl{[p-cymene] [(S,S)-Ts-DPEN]}	203,400.00	kg	79.11		0.001	1.00	16,090.40	
27	borane (S)-20	893.60	L	9,877.16		0.001	1.00	8,826.27	
28	pentane	65.92	L	79,017.27		0.10	0.70	364,598.87	
					Total			2,868,124.59	
					Total RM Costs (TRM)	5,736,249.18			




Figure S 41: Simplified process flow diagram for the biotechnological production of ergorgiaene

References:

- 1 J. Rinkel, P. Rabe, X. Chen, T. G. Köllner, F. Chen and J. S. Dickschat, *Chemistry* (Weinheim an der Bergstrasse, Germany), 2017, **23**, 10501–10505.
- 2 Y. Yamada, S. Arima, T. Nagamitsu, K. Johnmoto, H. Uekusa, T. Eguchi, K. Shin-ya, D. E. Cane and H. Ikeda, *The Journal of antibiotics*, 2015, **68**, 385–394.
- 3 L. Zimmermann, A. Stephens, S.-Z. Nam, D. Rau, J. Kübler, M. Lozajic, F. Gabler, J. Söding, A. N. Lupas and V. Alva, *Journal of molecular biology*, 2018, **430**, 2237–2243.
- 4 D. T. Jones, *Journal of molecular biology*, 1999, **292**, 195–202.
- 5 T. Nugent and D. T. Jones, *BMC bioinformatics*, 2009, **10**, 159.